Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cogstate Ltd ( (AU:CGS) ) just unveiled an update.
Cogstate Ltd reported record revenue of $23.9 million for the first half of 2025, a 19% increase compared to the previous corresponding period, driven largely by a 27% rise in clinical trials revenue. While healthcare revenue saw a decline of 44%, the company’s EBIT surged by 167% to $4.8 million, indicating strong operational performance. The significant growth in sales contracts and a robust contracted revenue backlog underscores Cogstate’s solid market positioning, although the healthcare segment faces challenges. The company’s cash reserves of $34.2 million at the end of 2024 further strengthen its financial stability.
More about Cogstate Ltd
Cogstate Ltd is a company operating in the cognitive science industry, primarily providing cognitive testing solutions. The company’s products and services focus on supporting clinical trials and healthcare, with a particular emphasis on cognitive assessments for clinical research and healthcare markets.
YTD Price Performance: 14.71%
Average Trading Volume: 8,868
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $135.3M
Find detailed analytics on CGS stock on TipRanks’ Stock Analysis page.
